Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
To address the challenges in cancer immunotherapy, such as limited clinical effectiveness and complex antigen/therapeutic delivery, Creative Biolabs provides cost-effective precision dendritic cell (DC) vaccine development services. We help you accelerate the development of highly specific and effective anti-tumor immune responses through advanced DC engineering and innovative smart drug delivery technologies.
Dendritic cells (DCs) are pivotal antigen-presenting cells that orchestrate robust anti-tumor immune responses. Despite their potential, conventional DC vaccines have shown modest clinical efficacy, often hampered by issues like inefficient antigen presentation, poor DC migration, and the immunosuppressive tumor microenvironment. Developing precision DC vaccines with smart drug delivery is crucial to overcome these limitations, enabling targeted antigen delivery and enhanced immune activation for more effective cancer treatment, leveraging advancements in gene therapy and nanotechnology.
Fig.1 DC vaccine injection and function process.1
Creative Biolabs' Precision DC Vaccine Development Services provide comprehensive solutions to empower your cancer immunotherapy projects. We deliver tailored strategies designed to elicit potent, specific anti-tumor immunity. You can expect optimized DC vaccine constructs, robust in vitro validation data, and detailed in vivo efficacy reports. Our meticulous quality assurance guarantees the integrity and functionality of every component, ensuring reliable and reproducible results.
We utilize advanced bioinformatics to identify optimal TAAs or neoantigens. Antigens are then synthesized as peptides, recombinant proteins, or prepared as genetic constructs (DNA/RNA) for subsequent loading onto DCs. The outcome is highly specific and immunogenic antigen material ready for DC pulsing or transfection.
DCs are differentiated ex vivo from patient-derived PBMCs or chosen cell lines. We employ proprietary protocols to ensure high yield and purity of immature DCs. This step yields a population of highly viable and antigen-responsive immature DCs.
Antigens are loaded onto DCs via various methods including pulsing with peptides/proteins, electroporation of nucleic acids, or conjugation with smart delivery systems. Subsequently, DCs are matured using optimized cocktails to enhance their antigen-presenting and co-stimulatory capabilities. The expected outcome is a population of mature, antigen-loaded DCs with potent immune stimulatory properties.
For enhanced targeting and delivery, antigens or DC-stimulating agents can be encapsulated within or conjugated to smart delivery vehicles, such as peptide-conjugated PAMAM dendrimers. This innovative approach ensures precise delivery to DCs in vivo or enhances ex vivo loading efficiency. This step yields DCs armed with enhanced targeting capabilities and improved immunogenicity.
Rigorous quality control checks are performed at each stage, including cell viability, phenotype (expression of MHC and co-stimulatory molecules), antigen uptake, and cytokine secretion. Final DC vaccine products undergo extensive in vitro functional assays, such as T-cell proliferation and cytokine profiling, to confirm immune activation potential. This ensures a high-quality, functional DC vaccine product ready for in vivo studies or clinical application.
The formulated DC vaccine is tested in relevant animal models (e.g., syngeneic tumor models) to assess its ability to induce anti-tumor responses, inhibit tumor growth, and establish immunological memory. This provides crucial data on the therapeutic potential and safety of the vaccine.
Our Precision DC Vaccine Development Services are broadly categorized into two main profiles, each designed to meet distinct project needs and therapeutic strategies.
This service focuses on the ex vivo manipulation of dendritic cells. We specialize in isolating, expanding, loading, and maturing DCs with tumor antigens outside the body, ensuring optimal antigen presentation and robust T-cell activation. This includes fine-tuning maturation cocktails and antigen loading strategies to maximize vaccine potency before administration.
This profile emphasizes the design and development of smart delivery systems, such as peptide-conjugated PAMAM dendrimers, to precisely target and activate dendritic cells in vivo. We focus on developing carriers that efficiently deliver antigens or immune-modulating agents directly to DCs within the patient, enhancing their ability to initiate and sustain anti-tumor immune responses, thereby overcoming challenges associated with traditional ex vivo approaches.
Q: What materials do I need to provide to start a Precision DC Vaccine Development project with Creative Biolabs?
Creative Biolabs is dedicated to accelerating your breakthroughs in cancer immunotherapy. Our Precision DC Vaccine Development Services, enhanced by smart drug delivery technologies, offer a powerful and precise approach to addressing the unmet needs in oncology. Partner with us to leverage our extensive expertise, state-of-the-art platforms, and commitment to scientific excellence to drive your project towards success. For more details about our precision DC vaccine development services, please don't hesitate to get in touch with us.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
